Country: Canada
Language: English
Source: Health Canada
BRIMONIDINE TARTRATE
AA PHARMA INC
S01EA05
BRIMONIDINE
0.15%
SOLUTION
BRIMONIDINE TARTRATE 0.15%
OPHTHALMIC
5ML/10ML
Prescription
ALPHA-ADRENERGIC AGONISTS
Active ingredient group (AIG) number: 0131859003; AHFS:
APPROVED
2008-07-15
_BRIMONIDINE P (Brimonidine Tartrate ophthalmic solution) _ _Page 1 of 30 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr BRIMONIDINE P Brimonidine Tartrate ophthalmic solution Sterile Solution, 0.15% w/v, for ophthalmic use Relatively Selective α 2 -Adrenoceptor Agonist ATC code: S01EA05 AA PHARMA INC 1165 Creditstone Road, Unit #1 Vaughan, Ontario L4K 4N7 Date of Initial Authorization: July 15, 2008 Date of Revision: August 29, 2023 Submission Control Number: 273876 _BRIMONIDINE P (Brimonidine Tartrate ophthalmic solution) _ _Page 2 of 30 _ RECENT MAJOR LABEL CHANGES None at the time of the most recent authorization. TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .................................................................................................................. 4 1.1 Pediatrics ................................................................................................................. 4 1.2 Geriatrics .................................................................................................................. 4 2 CONTRAINDICATIONS ..................................................................................................... 4 4 DOSAGE AND ADMINISTRATION ..................................................................................... 4 4.1 Dosing Considerations ...................................................................................................... 4 4.2 Recommended Dose and Dosage Adjustment ................................................................. 5 4.4 Administration ................................... Read the complete document